Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.
Science 37 Holdings Inc. (SNCE) leads the transformation of clinical research through its decentralized trial platform combining telemedicine and networked trial solutions. This news hub provides investors and healthcare professionals with essential updates on the company's operational developments and industry leadership.
Access real-time announcements about clinical trial milestones, regulatory compliance achievements, and strategic partnerships. Our curated collection features earnings reports, technology innovations like the Metasite™ platform, and patient enrollment breakthroughs that demonstrate Science 37's impact on modern clinical research.
Key updates include progress in decentralized trial models, collaborations with medical institutions, and advancements in virtual patient recruitment. Bookmark this page to stay informed about how SNCE continues to redefine clinical trial accessibility while maintaining rigorous quality standards across all operations.
Science 37 Holdings, Inc. (SNCE) reported a 50% year-over-year revenue growth of $18.7 million for Q1 2022. Net bookings dropped to $30.6 million, influenced by cancellations of major COVID studies, down from $40.7 million in Q1 2021. The company recorded a net income of $44.9 million, driven by a non-cash gain of $75.5 million from revaluation of earn-out liability, contrasting with a net loss of $6.8 million in the previous year. Adjusted net loss increased to $23.3 million. Science 37 maintains its revenue guidance of $86 million to $96 million for FY 2022 while expecting adjusted EBITDA of $(65) million to $(69) million.
Science 37 Holdings, Inc. (Nasdaq: SNCE) will report its first quarter 2022 financial results on May 9, 2022, before market opening. A conference call with management will occur at 5:00 a.m. PT / 8:00 a.m. ET, available via telephone and webcast. Science 37 specializes in decentralized clinical trials, aiming to enhance access and efficiency in clinical research through its Agile Clinical Trial Operating System. The company reports significant advancements in trial enrollment speed, participant retention, and diversity, which are integral to its operational model.
Science 37 Holdings, Inc. (SNCE) announced the addition of Dr. Shaalan Beg to its Global Management Team as Vice President, Oncology. Dr. Beg brings extensive experience from the University of Texas, where he served as Medical Director and Associate Professor. His expertise will enhance Science 37's capability in decentralized oncology studies, aligning with the company's mission to make clinical research more accessible. Science 37's Agile Clinical Trial Operating System is designed for faster enrollment and improved patient retention, helping to transform cancer research.
Science 37 Holdings, Inc. (SNCE) reported robust financial results for Q4 and full year 2021, with revenue rising 83% to $20.4 million in Q4 and 151% to $59.6 million for the year. Net bookings also surged, achieving 102% growth for the quarter at $43.2 million and 194% annual growth at $163.9 million. However, the company recorded a net loss of $65.1 million in Q4 and $94.3 million for the year. Looking forward, Science 37 anticipates revenue between $86 and $96 million for 2022, signaling confidence in continued growth.
Science 37 Holdings, Inc. (Nasdaq: SNCE) will announce its fourth quarter and full year 2021 financial results on March 22, 2022, before market open. A conference call will follow at 5:00 a.m. PT / 8:00 a.m. ET, accessible by dialing (844) 467-7754 for domestic callers and (270) 215-9366 for international participants. Investors can view a live and archived webcast on the Science 37 Investor Relations website. The company aims to enhance patient access to clinical research through its Agile Clinical Trial Operating System, which promotes faster enrollment and diverse patient populations.
Science 37 Holdings, Inc. (Nasdaq: SNCE) announced its participation in the Cowen 42nd Annual Health Care Conference, scheduled for March 7, 2022, at 1:30 p.m. Eastern Time. The presentation will be accessible via a live and archived webcast on the company’s Investor Relations website. Science 37 aims to improve access to clinical trials through its Agile Clinical Trial Operating System, which supports diverse patient populations and faster enrollment rates. The company focuses on decentralized trials to enhance efficiencies in clinical research.
Science 37 Holdings, Inc. (Nasdaq: SNCE) significantly expanded its clinical trial network, adding nearly 35,000 physician-providers since January 2021, which enhances agile trial execution.
By contracting with over 800 healthcare organizations, the company now has access to 28 million patients globally. This expansion aims to reduce the infrastructure barriers for physician participation in clinical trials, allowing for patient enrollment up to 15 times faster than traditional methods, and the potential to conduct more complex studies.
Science 37 Holdings (Nasdaq: SNCE) has partnered with physIQ to enhance digital clinical trials using remote biosensors and machine learning. The collaboration aims to create predictive digital biomarkers that assist in demonstrating treatment safety and efficacy. With physIQ's established FDA-approved platform and capabilities in processing real-time biosensor data, this partnership is expected to strengthen Science 37's Agile Clinical Trial Operating System, facilitating faster trial results and improved patient monitoring.
FAQ
What is the market cap of Science 37 Holdings (SNCE)?
